D&D Pharmatech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
D&D Pharmatech is listed on KOSDAQ and classified under Industrials, Commercial Services. Its market value is US$1.5B. In FY2025 it reported revenue of US$3.2M and an operating loss of US$25.7M.
A written company profile is not available yet; the facts above come from exchange and DART data.
D&D Pharmatech in five facts
Where is D&D Pharmatech listed and in which sector?
D&D Pharmatech (Korean name: 디앤디파마텍) trades under KRX code 347850 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is D&D Pharmatech?
Its market capitalisation was US$1.5B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were D&D Pharmatech's latest annual revenue and operating profit?
For fiscal year 2025, D&D Pharmatech reported revenue of US$3.2M, an operating loss of US$25.7M and a net loss of US$18.1M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 62.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 8
- Report on securities held by executives/major shareholdersSep 8
- [Amended] Supply contract signed
D&D Pharmatech updated a previously disclosed supply contract with Pfizer Inc., now worth US$1.7M, about 58.79% of its recent annual revenue, running through Feb 2028.
Supply contract · Jul 14 · 2 versions - Material event report (decision to redeem own convertible bonds early)Capital raise · Jun 15
- [Attachment amended] Material event report (convertible bonds)Capital raise · Apr 22
- Material event report (convertible bonds)
D&D Pharmatech disclosed convertible bonds to raise US$154M, about 11.1% of its market value.
Capital raise · Apr 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
D&D Pharmatech reported consolidated results for FY2025: revenue of US$2.98M (−62.42% year on year), an operating loss of US$23.6M and a net loss of US$16.6M.
Earnings · Feb 13